Our Recommendations
New Publications
- Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination (2022)
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- Manual del Vacunador Vacuna MODERNA para uso pediátrico de 6 a 11 años Campaña Nacional de Vacunación contra la COVID-19 (2022)
- Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022 (2022)
- WHO Science in 5 Episode #78 - mRNA technologies (2022)
Filter
132
Featured
Recommendations
24
Language
Document type
Guidelines
44
Fact sheets
43
Studies & Reports
14
Resource Platforms
11
Manuals
7
Infographics
5
Situation Updates
4
Videos
3
Training Material
1
Countries / Regions
Germany
16
Brazil
8
Russia
8
West and Central Africa
6
East and Southern Africa
6
Argentina
6
India
6
Mozambique
3
Africa
3
Latin America and the Carribbean
2
Middle East and North Africa
2
Western and Central Europe
2
South Sudan
2
Turkey
1
Kazakhstan
1
Global
1
Haiti
1
Guinea-Bissau
1
France
1
United Kingdom
1
Portugal
1
Spain
1
South Korea
1
Belarus
1
Vietnam
1
Angola
1
Authors & Publishers
Publication Years
Category
COVID-19
52
Guidelines
11
Information, Education and Communication (IEC)
7
Studies & Reports
4
x MEDBOX Issue Brief & Annual Reports x
2
Women & Child Health
2
Countries
1
Policies
1
Immunization
1
Toolboxes
Vaxzevria (Astra Zeneca)
26
Research & Pipeline
26
Biontech/Pfizer Comirnaty
23
Inactivated COVID-19 Vaccines
18
mRna Vaccines general
14
Vector-based Vacines General
14
Moderna
13
Johnson & Johnson
8
Covaxin
6
Sputnik V
3
El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.
Organización Mundial de la Salud. (2022). Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022.
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method...
COVID-19 vaccine tracker and landscape
recommended
The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline.
The COVID-19 vaccine tracker:
Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future?
first issued 18 August 2022
CONVIDECIA is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2. It is administered as a single dose.
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th...
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
29 April 2022
What are the new vaccines in the pipeline? What are the challenges to turning vaccines into vaccination ? What timelines can we expect for future vaccines? WHO’s Dr Katherine O’Brien explains in Science in 5.
This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and procedures, create task forces and alliances to maximize ...
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...
